

World Journal of Clinical Cases  
Editorial Office  
Science Editor,  
Company Editor-in-Chief, Editorial Office

January 26, 2021

Dear Lian-Sheng Ma,

Thank you very much for providing us the comments of the reviewers that have improved the quality of the manuscript that we are submitting. We have corrected the manuscript following the suggestions of the reviewers, the Science editor and the Company Editor-in-Chief.

We have highlighted in red the corrected sections in the revised form of the manuscript.

Thank again and look forward to have a favorable response from you.

Best regards,

Esteban C. Gabazza, MD, PhD  
Department of Immunology  
Mie University  
Edobashi 2-174  
Tsu, Mie 514 8507, Japan;  
Phone: +81-59-231-5037;  
Fax: +81-59-231-5225.  
E-mail: [gabazza@doc.medic.mie-u.ac.jp](mailto:gabazza@doc.medic.mie-u.ac.jp).

### **Response to Reviewer #1:**

#### **Comment 1**

**Scientific Quality:** Grade B (Very good)

**Language Quality:** Grade B (Minor language polishing)

**Conclusion:** Accept (High priority)

**Specific Comments to Authors:** This is an interesting Case of Euglycemic Diabetic Ketoacidosis Induced by a Sodium-Glucose Co-transporter 2 Inhibitor. Although it a well known complication of this group of drugs it is well written

#### **Response**

We are very thankful for the favorable comments of the reviewer that has improved the quality of the manuscript.

#### **Comment 2**

##### **Language quality**

Please resolve all language issues in the manuscript based on the peer review report. Please be sure to have a native-English speaker edit the manuscript for grammar, sentence structure, word usage, spelling, capitalization, punctuation, format, and general readability, so that the manuscript's language will meet our direct publishing needs.

#### **Response**

The manuscript has been revised by a native English speaker that is also a physician.

### **Editorial Office's comment: Science editor:**

#### **Comment 1**

1 Scientific quality: The manuscript describes a case report of the euglycemic diabetic ketoacidosis induced by a sodium-glucose co-transporter 2 inhibitor that prompted the diagnosis of fulminant type 1 diabetes mellitus. The topic is within the scope of the WJCC. (1) Classification: Grade B; (2) Summary of the Peer-Review Report: This is an interesting case of euglycemic diabetic ketoacidosis induced by a sodium-glucose co-transporter 2 inhibitor. Although it a well-known complication of this group of drugs it is well written; and (3) Format: There is 1 table. A total of 16 references are cited, including 3 references

published in the last 3 years. There are no self-citations. 2 Language evaluation: Classification: Grade B. No language editing certificate was provided.

### **Response**

The manuscript has been revised by a native English speaker that is also a physician.

### **Comment 2**

3 Academic norms and rules: The authors didn't provide the written informed consent. No academic misconduct was found in the Bing search. 4 Supplementary comments: This is an unsolicited manuscript. No financial support was obtained for the study. The topic has not previously been published in the WJCC.

### **Response**

We have provided now the informed consent of the patient as suggested.

### **Comment 3**

5 Issues raised: (1) PMID and DOI numbers are missing in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. Please revise throughout; and (2) Authors should always cite references that are relevant to their study. Please check and remove any references that not relevant to this study. 6 Recommendation: Conditional acceptance.

### **Response**

We have provided the PMID and DOI of the references.

**Editorial Office's comment: Editorial office director:**

### **Comment 1**

**(3) Company editor-in-chief:** I have reviewed the Peer-Review Report, the full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Clinical Cases, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s)

for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors. Before its final acceptance, the author(s) must provide the Signed Informed Consent Form(s) or Document(s). For example, authors from China should upload the Chinese version of the document, authors from Italy should upload the Italian version of the document, authors from Germany should upload the Deutsch version of the document, and authors from the United States and the United Kingdom should upload the English version of the document, etc.

**Response**

We have provided the informed consent of the patient.

**Comment 2**

The title of the manuscript is too long and must be shortened to meet the requirement of the journal (Title: The title should be no more than 18 words).

**Response**

We have shortened the title of the manuscript as suggested.